Trial Type: Colon Cancer

A phase 1/2 study of SAR444200, an anti-GPC3/CD3 bispecific antibody in patients with advanced solid tumors

Anti claudin antibody drug conjugate AZD0901 for solid tumors expressing claudin 18.2 (Port trial)

RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNNT1222-01)

A Randomized Study of Botensilimab with and without Balstilimab (Agen2034) for the MSS Colorectal Cancer without Liver Metastases after FOLFOX and FOLFIRI

Encorafenib and Cetuximab with or Without Nivolumab) for Patients with Previously Treated, Microsatellite Stable, advanced Colorectal Cancer

Phase I/II study of DF1001 Trinket immunotherapy for HER2 expressing tumors: Open cohorts are for breast cancer, colon cancer and NSCLC